Organogenesis Holdings (ORGO) Non Operating Income (2017 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Non Operating Income of $418000.0 for Q1 2026, down 56.59% year-over-year from $963000.0 in Q1 2025, and up 202.9% quarter-over-quarter from $138000.0 in Q4 2025.
Organogenesis Holdings (ORGO) Non Operating Income (2017 - 2026) Analysis & Trends
Organogenesis Holdings' Non Operating Income history runs 10 years deep, the most recent figure standing at $418000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 56.59% year-over-year to $418000.0; the TTM figure through Mar 2026 stood at $1.7 million (up 2572.86% YoY), while the FY2025 annual figure was $2.3 million, up 249.34% from the prior year.
- Non Operating Income for Q1 2026 stood at $418000.0, up from $138000.0 in the prior quarter.
- The five-year high for Non Operating Income was $963000.0 in Q1 2025, with the low at -$751000.0 in Q2 2022.
- The 5-year median for Non Operating Income is -$419000.0 (2024), against an average of -$175529.4.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income tumbled 1563.89% in 2023, then soared 305.88% in 2025.
- Organogenesis Holdings' Non Operating Income stood at $36000.0 in 2022, then sank by 1563.89% to -$527000.0 in 2023, then soared by 106.45% to $34000.0 in 2024, then jumped by 305.88% to $138000.0 in 2025, then soared by 202.9% to $418000.0 in 2026.
- Business Quant data shows ORGO's Non Operating Income at $418000.0 in Q1 2026, $138000.0 in Q4 2025, and $433000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Organogenesis Holdings | 242.55 Mn | 195.71 Mn | 20.08 Mn | 112,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 112,000.00 |
| Mar 31, 2026 | 418,000.00 |
| Dec 31, 2025 | 138,000.00 |
| Sep 30, 2025 | 433,000.00 |
| Jun 30, 2025 | 742,000.00 |
| Mar 31, 2025 | 963,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Sep 30, 2024 | -419,000.00 |
| Jun 30, 2024 | -648,000.00 |
| Mar 31, 2024 | -491,000.00 |
| Dec 31, 2023 | -527,000.00 |
| Sep 30, 2023 | -413,000.00 |
| Jun 30, 2023 | -566,000.00 |
| Mar 31, 2023 | -626,000.00 |
| Dec 31, 2022 | 36,000.00 |
| Sep 30, 2022 | -567,000.00 |
| Jun 30, 2022 | -751,000.00 |
| Mar 31, 2022 | -740,000.00 |
| Dec 31, 2021 | -862,000.00 |
| Sep 30, 2021 | -3.38 Mn |